Hematologic Diseases

Expanding access to hematopoietic stem cell transplants for patients in need

Program
Pre-Clinical
Clinical
Commercial

  • HPC, Marrow

    Phase 2
    0
    I
    II
    III
    IV

    A first-in-human, multi-center, single-arm study of HLA-partially-matched allogenic cryopreserved deceased donor bone marrow to treat patients with hematologic malignancies. The goal of this clinical trial is to determine the safety and feasibility of allogeneic transplantation with bone marrow from a deceased donor in patients with acute leukemias. Patients will either receive myeloablative conditioning or reduced intensity conditioning regimen prior to the transplant. Patients will be followed for 56 days for safety endpoints and remain in follow-up for one year.

    Related Products

    HPC, Marrow

    Partners

Musculoskeletal Defects

Leveraging Ossium's cell therapy expertise to develop next-generation viable bone matrix allografts

Program
Pre-Clinical
Clinical
Commercial

  • OssiGraft™ Viable Bone Matrix Allografts

    Commercial
    0
    I
    II
    III
    IV

    OssiGraft™ and OssiGraft Prime™ are viable bone matrix allografts containing a formulation of viable cryopreserved cells in their native bone niche. OssiGraft™ and OssiGraft Prime™ are available in a variety of sizes and are intended for the repair, replacement, and reconstruction of musculoskeletal defects of the spine, pelvis, or extremities. These products are minimally manipulated HCT/Ps regulated by the FDA under section 361 of the Public Health Service Act and 21 CFR Part 1271 and do not require premarket authorization. Ossium Health complies with Good Tissue Practices and is an FDA-registered Tissue Establishment.

    Related Products

    OssiGraft™ Viable Bone Matrix

    OssiGraft Prime™ Viable Bone Matrix

Partner with Us

Let's work together to revolutionize treatment for patients suffering from hematologic diseases, organ transplant rejection, and musculoskeletal defects.